Conformis Provides Business Update and Reports Preliminary Results for Fourth Quarter and Full-Year 2022
BILLERICA, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, provided today a business update and reported preliminary financial results for the fourth quarter and year ended December 31, 2022.
- BILLERICA, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, provided today a business update and reported preliminary financial results for the fourth quarter and year ended December 31, 2022.
- We are also providing an update of our commercial progress of the new business model through year end.
- Preliminary Fourth Quarter 2022 Summary:
Total revenue of approximately $17.4 million, up 13% year-over-year on a reported basis and 14% on a constant currency basis; includes non-recurring licensing revenue associated with the settlement and licensing agreement with Medacta. - The Company currently expects to report its full financial results for the fourth quarter and the year ended 2022 on March 1, 2023.